



6-27-07

1649#

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

IFW

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/539,634
	Filing Date	December 9, 2005
	First Named Inventor	Leon Carlock et al.
	Art Unit	1649
	Examiner Name	Chang-Yu Wang
Total Number of Pages in This Submission	Attorney Docket Number	4981-000011/NP

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form HDP-1449; Copy of Int'l Search Report; 4 foreign patent references; 67 other documents; return postcard.		
<table border="1"><tr><td>Remarks</td><td>The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750.</td></tr></table>			Remarks	The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750.
Remarks	The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750.			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Harness, Dickey & Pierce, P.L.C.		
Signature			
Printed name	David L. Suter		
Date	June 26, 2007	Reg. No.	30,692


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	David L. Suter	Express Mail Label No.	EV 755 416 792 US (6/26/2007)
Signature		Date	June 26, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 755 416 792 US



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL for FY 2007

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180

Complete if Known

Application Number	10/539,634
Filing Date	December 9, 2005
First Named Inventor	Leon Carlock et al.
Examiner Name	Chang-Yu Wang
Art Unit	1649
Attorney Docket No.	4981-000011/NP

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify) : _____

☒ Deposit Account Deposit Account Number: 08-0750 Deposit Account Name: Harness, Dickey & Pierce, P.L.C.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below

☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s)

☒ Credit any overpayments

Under 37 CFR 1.16 and 1.17

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee(\$)	Fee(\$)	Small Entity Fee(\$)	Fee(\$)	Small Entity Fee(\$)	
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Plant	200	100	300	150	160	80	_____
Reissue	300	150	500	250	600	300	_____
Provisional	200	100	0	0	0	0	_____

2. EXCESS CLAIM FEES

Fee Description

Each claim over 20 (including Reissues)

Fee (\$)
50

Small Entity Fee (\$)
25

Each independent claim over 3 (including Reissues)

200

100

Multiple dependent claims

360

180

Total Claims

Extra Claims

Fee(\$)

Fee Paid (\$)

_____ -20 or HP= 0 x _____ = 0

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims

Extra Claims

Fee(\$)

Fee Paid (\$)

_____ - 3 or HP= 0 x _____ = 0

HP = highest number of independent claims paid for, if greater than 3.

Multiple Dependent Claims

Fee (\$)	Fee Paid (\$)
_____	_____

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____	- 100 = 0 / 50 =	-2 (round up to a whole number)	x	= 0

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge) : Submission of Information Disclosure Statement

Fees Paid (\$)

180

SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	30,692	Telephone	(248) 641-1600
Name (Print/Type)	David L. Suter	Date	June 26, 2007		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Application No.: 10/539,634
Filing Date: December 9, 2005
Applicant: Leon Carlock et al.
Group Art Unit: 1649
Examiner: Chang-Yu Wang
Title: BIOACTIVE PEPTIDES AND UNIQUE IRES ELEMENTS FROM
MYELIN PROTEOLIPID PROTEIN PLP/DM20
Attorney Docket: 4981-000011/NP

Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION

The patents, publications and other information requested to be considered by the Office (except unpublished U.S. patent applications) are listed on Form 1449 attached hereto.

II. COPIES

A. ☒ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office; (iii) each unpublished U.S. application listed below in Section IV (i.e., including the specification, claims, and any drawing of the application, or that portion of the application which caused it to be listed, including any claims directed to that portion), except for such applications filed on or after June 30, 2003, pursuant to the Waiver of the Copy Requirement in 37 C.F.R. 1.98 (OG Notice dated October 19, 2004); and (iv) all other information or that portion which caused it to be listed.

06/27/2007 HVUONG1 00000032 10539634

01 FC:1806 180.00 0P

Serial No. 10/539,634

Page 1 of 5

B. ☐ Any patents, publications or other information which are listed on Form 1449 or on the copies of PTO-892, but which are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Serial Number

U.S. Filing Date

C. ☐ This is a PCT application in the entry of the National Phase in the United States. A copy of the International Search Report is attached for the Examiner's information. The documents listed on the International Search report are listed on the attached Form 1449 for consideration by the Examiner and for listing on any patent resulting from this application. If the International Search report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g).)

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

A. ☒ Except as may be indicated below in (B), all of the patents, publications or other information are in the English language (concise explanation not required).

B. ☒ A concise explanation of the relevance of each patent, publication or other information listed that is not in the English language is as follows (see 37 C.F.R. § 1.98(a)(3)):

1. ☐ See the attached foreign patent office communication from a counterpart foreign application:

2. ☐ English translations are provided:

3. ☒ Other:

English language machine translations are provided for JP 06-211683 and JP 09-263543.

C. ☒ The following additional information is provided for the Examiner's consideration.

International Search Report completed December 12, 2006 in corresponding International Application No. PCT/US03/39873.

IV. CROSS REFERENCE TO RELATED APPLICATION(S)

A. ☐ The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does (do) not waive the confidentiality provisions of 35 U.S.C. § 122.

Serial No.

Filing Date

Inventor(s)

V. THIS IDS IS BEING FILED UNDER

A. ☐ **37 C.F.R. § 1.97(b):** (check only one box)

1. ☐ within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. § 1.97(b)(1)). No fee or certification is required.
2. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or certification is required.
3. ☐ before the mailing of a first Office Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below; or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
4. ☐ before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No fee or certification is required.

B. ☒ **37 C.F.R. § 1.97(c):** (check only one box)

before the mailing date of either any Final Office Action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution.

1. ☒ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
2. ☐ See the certification below. No fee is required.

C. ☐ 37 C.F.R. § 1.97(d):

after the mailing date of either a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, yet on or before payment of the issue fee.

1. ☐ See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e): (check only one box)

The undersigned hereby certifies that:

A. ☐ each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. 1.704(d) below in section VII, if applicable; or

B. ☐ no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).

C. ☐ some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.

VII. STATEMENT UNDER 37 C.F.R. 1.704(d)

The undersigned hereby states that:

☐ each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this IDS.

VIII. PAYMENT OF FEES (check only one box, if applicable)

A. ☒ A check in the amount of \$180.00 is enclosed for the above-identified fee.

B. ☐ Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-identified fee. A duplicate copy of this paper is attached.


Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. § 1.16 or § 1.17 to Deposit Account No. 08-0750.

The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.


Respectfully submitted,

Dated: June 26, 2007

By: 
David L. Suter
Reg. No. 30,692

Harness, Dickey & Pierce, P.L.C.
P.O. Box 828
Bloomfield Hills, Michigan 48303
(248) 641-1600

DLS/kq



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 6

ATTORNEY DOCKET NO.

4981-000011/NP

SERIAL No.

10/539,634

APPLICANT

Leon Carlock et al.

FILING DATE

December 9, 2005

GROUP

1649

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		5,242,798	09/07/1993	Sutcliffe		

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
1.		EP 0684310	11/29/1995	EPO		N/A	
2.		JP 06-211683	08/02/1994	Japan		X	
3.		JP 09-263543	10/07/1997	Japan		X	
4.		WO 96/34622	11/07/1996	WIPO		N/A	


OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
1.		Baumgartner et al. (1999). Molecular analysis of the porcine proteolipid protein (PLP) gene. Mamm Genome. 10: 895-899
2.		Baumgartner et al. (2000). Structural analysis and transcript processing of the bovine proteolipid protein (PLP) gene. DNA Sequence. 10(6): 379-385
3.		Bizzozero et al. (2002). Mass- spectrometric analysis of myelin proteolipids reveals new features of this family of palmitoylated membrane proteins. J Neurochem. 81: 636-645
4.		Blesch et al. (2002). Neurotrophic factors, gene therapy, and neural stem cells for spinal cord repair. Brain Res Bull. 57(6): 833-838
5.		Boison et al. (1995). Adhesive properties of proteolipid protein are responsible for the compaction of CNS myelin sheaths. J Neurosci. 15(8): 5502-5513
6.		Bongarzone et al. (2001). Differential sensitivity in the survival of oligodendrocyte cell lines to overexpression of myelin proteolipid protein gene products. J Neurosci Res 65: 485-492
7.		Boucher et al. (2002). Proteolipid protein gene modulates viability and phenotype of neurons. J Neurosci. 22 (5): 1772-1783

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 2 of 6

ATTORNEY DOCKET No.	SERIAL No.
4981-000011/NP	10/539,634
APPLICANT	
Leon Carlock et al.	
FILING DATE	GROUP
December 9, 2005	1649

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
8.		Burne et al. (1996). Glial cells are increased proportionally in transgenic optic nerves with increased numbers of axons. J Neurosci. 16(6): 2064-2073
9.		Campagnoni et al. (1994). Isolation and characterization of a cDNA encoding the zebra finch myelin proteolipid protein. Neurochem Res. 19(8): 1061-1065
10.		Casaccia-Bonnet (2000). Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in development and disease. Glia. 29: 124-135
11.		De Louw et al. (2002). Developmental apoptosis in the spinal cord white matter in neonatal rats. Glia. 37: 89-91
12.		Dickinson et al. (1996). Oligodendrocyte progenitors in the embryonic spinal cord express DM-20. Neuropathol Appl Neurobiol. 22: 188-198
13.		Diehl et al. (1986). Individual exons encode the integral membrane domains of human myelin proteolipid protein. Proc Natl Acad Sci USA. 83: 9807-9811
14.		Du et al. (2002). Oligodendrocytes as providers of growth factors. J Neurosci Res. 68: 647-654
15.		Edgar et al. (2002). Survival of, and competition between, oligodendrocytes expressing different alleles of the Plp gene. J Cell Biol. 158(4): 719-729
16.		Garbern (2007). Pelizaeus-Merzbacher disease: genetic and cellular pathogenesis. Cell Mol Life Sci 64: 50-65
17.		Gow et al. (1997). Conservation of topology, but not conformation, of the proteolipid proteins of the myelin sheath. J Neurosci. 17(1): 181-189
18.		Gudz et al. (2002). Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes. J Neurosci. 22(17): 7398-7407
19.		Hudson et al. (1987). Aberrant splicing of proteolipid protein mRNA in the dysmyelinating jimpy mutant mouse. Proc Natl Acad Sci USA. 84: 1454-1458
20.		Inoue et al. (1996). Cell death of oligodendrocytes or demyelination induced by overexpression of proteolipid protein depending on expressed gene dosage. Neurosci Res. 25: 161-172
21.		Jung et al. (1996). Monoclonal antibody O10 defines a conformationally sensitive cell-surface epitope of proteolipid protein (PLP): evidence that PLP misfolding underlies dysmyelination in mutant mice. J Neurosci. 16(24): 7920-7929
22.		Klugmann et al. (1997). Assembly of CNS myelin in the absence of proteolipid protein. Neuron. 18: 59-70

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 3 of 6

ATTORNEY DOCKET No.

4981-000011/NP

SERIAL No.

10/539,634

APPLICANT

Leon Carlock et al.

FILING DATE

December 9, 2005

GROUP

1649

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
23.		Knapp et al. (1999). Programmed cell death without DNA fragmentation in the jimpy mouse: secreted factors can enhance survival. Cell Death Differ. 6: 136-145
24.		Laursen et al. (1984). The structure of bovine myelin proteolipid and its organization in myelin. Proc Natl Acad Sci USA. 81: 2912-2916
25.		Le Bras et al. (2005). Oligodendrocyte development in the embryonic brain: the contribution of the PLP lineage. Int J Dev Biol 49: 209-220
26.		Lees et al. (1983). Amino acid sequence of bovine white matter proteolipid. Arch of Bioc and Biop. 226(2): 643-656
27.		Lepage et al. (1986). Purification and characterization of minor brain proteolipids: use of fast atom bombardment-mass spectrometry for peptide sequencing. Biochimie. 68: 669-686
28.		Limón et al. (1997). High-titer retroviral vectors containing the enhanced green fluorescent protein gene for efficient expression in hematopoietic cells. Blood 90(9): 3316-3321.
29.		Liu et al. (2000). Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc Natl Acad Sci USA. 97(11): 6126-6131
30.		Macklin et al. (1987). Structure and expression of the mouse myelin proteolipid protein gene. J Neurosci Res. 18: 383-394
31.		Macklin et al. (1990). Structure and expression of the mouse myelin proteolipid protein gene. Annals New York Acad Sci 605(1): 183-193
32.		McLaughlin et al. (2002). Evidence for possible interactions between PLP and DM20 within the myelin sheath. Glia. 39: 31-36
33.		Milner et al. (1985). Nucleotide sequences of two mRNAs for rat brain myelin proteolipid protein. Cell. 42: 931-939
34.		Nadon et al. (1994). A combination of PLP and DM20 transgenes promotes partial myelination in the jimpy mouse. J Neurochem. 63: 822-833
35.		Nadon et al. (1990). A point mutation in the proteolipid protein gene of the 'shaking pup' interrupts oligodendrocyte development. Development 110: 529-537
36.		Nadon et al. (1997). Myelin proteolipid DM20: evidence for function independent of myelination. Int J Dev Neurosci. 15(3): 285-293
37.		Nakao et al. (1995). Expression of proteolipid protein gene is directly associated with secretion of a factor influencing oligodendrocyte development. J Neurochem. 64: 2396-2403

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 4 of 6

ATTORNEY DOCKET No.

4981-000011/NP

SERIAL No.

10/539,634

APPLICANT

Leon Carlock et al.

FILING DATE

December 9, 2005

GROUP

1649

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
38.		Nave et al. (1987). Splice site selection in the proteolipid protein (PLP) gene transcript and primary structure of the DM-20 protein of central nervous system myelin. Proc Natl Acad Sci USA. 84: 5665-5669
39.		Okano (2002). Stem cell biology of the central nervous system. J Neurosci Res. 69: 698-707
40.		Roy et al. (2000). Promoter-targeted selection and isolation of neural progenitor cells from the adult human ventricular zone. J Neurosci Res. 59: 321-331.
41.		Schliess et al. (1991). Evolution of the myelin integral membrane proteins of the central nervous system. Biol Chem. 372: 865-874
42.		Schweitzer et al. (2006). Evolution of myelin proteolipid proteins: gene duplication in teleosts and expression pattern divergence. Mol Cell Neurosci. 31: 161-177
43.		Sinoway et al. (1994). Tissue lipoproteins revisited: new proteolipid protein gene family members in elasmobranchs. Neurochem Res. 19(8): 1047-1054
44.		Skoff (1982). Increased proliferation of oligodendrocytes in the hypomyelinated mouse mutant-jimpy. Brain Research. 248: 19-31.
45.		Skoff et al. (2004) The myelin proteolipid protein genes modulates apoptosis in neural and non-neural tissues. Cell Death Diff. 11: 1247-1257
46.		Skoff et al. (2004). Analyses of proteolipid protein mutants show levels of proteolipid protein regulate oligodendrocytes number and cell death in vitro and in vivo. Neurochem Res. 29(11): 2095-2103
47.		Smith et al. (1984). Structure of the proteolipid protein extracted from bovine central nervous system myelin with nondenaturing detergents. J Neurochem. 42(2): 306-313
48.		Stecca et al. (2000). The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin. J Neurosci. 20(11): 4002-4010
49.		Tang et al. (1996). Cloning and expression of the proteolipid protein DM20 cDNA from the brain of the rainbow trout, Oncorhynchus mykiss. Brain Res Mol Brain Res. 41: 134-139
50.		Timsit et al. (1992). DM-20 mRNA is expressed during the embryonic development of the nervous system of the mouse. J Neurochem. 58: 1172-1175
51.		Tohyama et al. (2000). Phylogenetic relation of lungfish indicated by the amino acid sequence of myelin DM20. Mol Brain Res. 80: 256-259

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 5 of 6

ATTORNEY DOCKET NO.	SERIAL NO.
4981-000011/NP	10/539,634
APPLICANT	
Leon Carlock et al.	
FILING DATE	GROUP
December 9, 2005	1649

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
52.		Tohyama et al. (1999). Gene structure and amino acid sequence of Latimeria chalumnae (coelacanth) myelin DM20: phylogenetic relation of the fish. Neurochem Res. 24(7): 867-873
53.		Tosic et al. (1997). Intracellular transport of the DM-20 bearing shaking pup (shp) mutation and its possible phenotypic consequences. J Neurosci Res. 50:844-852
54.		Tosic et al. (1994). Paralytic tremor (pt): a new allele of the proteolipid protein gene in rabbits. J Neurochem. 63: 2210-2216
55.		Trapp et al. (1997). Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol. 137(2): 459-468
56.		Venkatesh et al. (2001). Molecular synapomorphies resolve evolutionary relationships of extant jawed vertebrates. Proc Natl Acad Sci. 98(20):11382-11387
57.		Vermeesch et al. (1990). Death of individual oligodendrocytes in jimpy brain precedes expression of proteolipid protein. Int J Dev Neurosci 12: 303-315
58.		Wahle et al. (1998). Cotranslational integration of myelin proteolipid protein (PLP) into the membrane of endoplasmic reticulum: analysis of topology by glycosylation scanning and protease domain protection assay. Glia 24: 226-235
59.		Whitehart et al. (1973). Amino and carboxyl-terminal amino acids of proteolipid proteins. J Neurochem. 20: 1303-1315
60.		Wiggins et al. (1974). NH ₂ -terminal analysis of Wolfgram and Folch-Lees proteolipid proteins. J Neurochem. 22: 337-340
61.		Wu et al. (1997). Novel green fluorescent protein (GFP) baculovirus expression vectors. Gene 190: 157-162.
62.		Yamada et al. (1999). Proteolipid protein gene product can be secreted and exhibit biological activity during early development. J Neurosci. 19(6): 2143-2151
63.		Yamada et al. (2001). Mutant PLP/DM20 cannot be processed to secrete PLP-related oligodendrocyte differentiation/survival factor. Neurochem Res. 26(6): 639-645
64.		Yamaguchi et al. (1996). Myelin proteolipid protein (PLP), but not DM-20, is an inositol hexakisphosphate-binding protein. J Biol Chem. 271(44): 27838-27846
65.		Yang et al. (1997). Proteolipid protein regulates the survival and differentiation of oligodendrocytes. J Neurosci. 17(6): 2056-2070
66.		Yin et al. (2006). Evolution of a neuroprotective function of central nervous system myelin. J Cell Biol 172(3): 469-478

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 6 of 6

ATTORNEY DOCKET NO.

4981-000011/NP

SERIAL No.

10/539,634

APPLICANT

Leon Carlock et al.

FILING DATE

December 9, 2005

GROUP

1649

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
67.		Yool et al. (2001). Myelin proteolipid proteins promote the interaction of oligodendrocytes and axons. J Neurosci Res. 63: 151-164

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.